Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Arnaud Lesegretain, Andrew Brunner, Aziz Benzohra & Amir T. Fathi. (2023) Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study. Leukemia & Lymphoma 0:0, pages 1-9.
Read now
Read now
Thomas P. Thomopoulos, Anthi Bouhla, Sotirios G. Papageorgiou & Vasiliki Pappa. (2021) Chronic myelomonocytic leukemia - a review. Expert Review of Hematology 14:1, pages 59-77.
Read now
Read now
Panagiotis T. Diamantopoulos, Ioannis Kotsianidis, Argiris Symeonidis, Vassiliki Pappa, Athanasios Galanopoulos, Dimitrios Gogos, Stamatios Karakatsanis, Helen Papadaki, Aikaterini Palla, Eleftheria Hatzimichael, Maria Dimou, Sotirios Papageorgiou, Sosana Delimpasis, Maria Papaioannou, Menelaos Papoutselis, Alexandra Kourakli, Dimitrios Tsokanas, Achilles Anagnostopoulos, Christos K. Kontos, Panayiotis Panayiotidis & Nora-Athina Viniou. (2019) Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. Leukemia & Lymphoma 60:7, pages 1721-1730.
Read now
Read now
Sonja Burgstaller, Reinhard Stauder, Thomas Kuehr, Alois Lang, Sigrid Machherndl-Spandl, Beate Mayrbaeurl, Thomas Noesslinger, Andreas Petzer, Peter Valent, Richard Greil & Josef Thaler. (2018) A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1. Leukemia & Lymphoma 59:5, pages 1121-1126.
Read now
Read now
Articles from other publishers (27)
Xinhui Zheng, Liwei Lv, Xiangjun Li & Erlie Jiang. (2022) Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis. Global Medical Genetics 09:02, pages 141-151.
Crossref
Crossref
A. Triguero, B. Xicoy, L. Zamora, MJ. Jiménez, O. García, M. Calabuig, M. Díaz-Beyá, J. Arzuaga, F. Ramos, A. Medina, T. Bernal, C. Talarn, R. Coll, R. Collado, T.Hua Chen, J. Borrás, S. Brunet, I. Marchante, V. Marco, F. López-Cadenas, M. Calbacho, A. Simiele, M. Cortés, MT. Cedena, M. Pedreño, C. Aguilar, C. Pedró, M. Fernández, C. Stoica, JM. Ribera & G. Sanz. (2022) Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria. Leukemia Research 116, pages 106836.
Crossref
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2022) Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. American Journal of Hematology 97:3, pages 352-372.
Crossref
Crossref
Konstantinos Liapis & Ioannis Kotsianidis. (2021) Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?. Frontiers in Oncology 11.
Crossref
Crossref
Douglas Tremblay, Noa Rippel, Jonathan Feld, Siraj M. El Jamal & John Mascarenhas. (2021) Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia. The Oncologist 26:5, pages 406-421.
Crossref
Crossref
Jihyun Kwon. (2021) Diagnosis and treatment of chronic myelomonocytic leukemia. BLOOD RESEARCH 56:S1, pages S5-S16.
Crossref
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2019) Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. American Journal of Hematology 95:1, pages 97-115.
Crossref
Crossref
Raphael Itzykson, Pierre Fenaux, David Bowen, Nicholas C.P. Cross, Jorge Cortes, Theo De Witte, Ulrich Germing, Francesco Onida, Eric Padron, Uwe Platzbecker, Valeria Santini, Guillermo F. Sanz, Eric Solary, Arjan Van de Loosdrecht & Luca Malcovati. (2018) Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. HemaSphere 2:6, pages e150.
Crossref
Crossref
Anthony M. Hunter, Ling Zhang & Eric Padron. (2018) Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. Current Treatment Options in Oncology 19:12.
Crossref
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2018) Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. American Journal of Hematology 93:6, pages 824-840.
Crossref
Crossref
Rita Assi, Hagop M. Kantarjian, Guillermo Garcia-Manero, Jorge E. Cortes, Naveen Pemmaraju, Xuemei Wang, Graciela Nogueras-Gonzalez, Elias Jabbour, Prithviraj Bose, Tapan Kadia, Courtney D. Dinardo, Keyur Patel, Carlos Bueso-Ramos, Lingsha Zhou, Sherry Pierce, Romany Gergis, Carla Tuttle, Gautam Borthakur, Zeev Estrov, Rajyalakshmi Luthra, Juliana Hidalgo-Lopez, Srdan Verstovsek & Naval Daver. (2018) A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. American Journal of Hematology 93:2, pages 277-285.
Crossref
Crossref
Matthieu Duchmann, Nolwenn Lucas, Raphael Itzykson & Eric Solary. 2018. Myelodysplastic Syndromes. Myelodysplastic Syndromes
65
79
.
Emma K. Davison & Jonathan Sperry. (2017) Natural Products with Heteroatom-Rich Ring Systems. Journal of Natural Products 80:11, pages 3060-3079.
Crossref
Crossref
Tamara K. Moyo & Michael R. Savona. (2017) Therapy for Chronic Myelomonocytic Leukemia in a New Era. Current Hematologic Malignancy Reports 12:5, pages 468-477.
Crossref
Crossref
Ana Alfonso, Guillermo Montalban-Bravo, Koichi Takahashi, Elias J. Jabbour, Tapan Kadia, Farhad Ravandi, Jorge Cortes, Zeev Estrov, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Carlos Bueso-Ramos, Sherry Pierce, Hagop Kantarjian & Guillermo Garcia-Manero. (2017) Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. American Journal of Hematology 92:7, pages 599-606.
Crossref
Crossref
Ana Alfonso, Guillermo Montalban-Bravo & Guillermo Garcia-Manero. (2017) Current management of patients with chronic myelomonocytic leukemia. Current Opinion in Oncology 29:1, pages 79-87.
Crossref
Crossref
Sonja Burgstaller. (2016) Treatment of chronic myelomonocytic leukemia. memo - Magazine of European Medical Oncology 9:4, pages 168-171.
Crossref
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2016) Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. American Journal of Hematology 91:6, pages 631-642.
Crossref
Crossref
Mrinal M. Patnaik & Ayalew Tefferi. (2016) Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clinic Proceedings 91:2, pages 259-272.
Crossref
Crossref
Piyanuch Kongtim, Uday Popat, Antonio Jimenez, Sameh Gaballa, Riad El Fakih, Gabriela Rondon, Julianne Chen, Carlos Bueso-Ramos, Gautam Borthakur, Naveen Pemmaraju, Guillermo Garcia-Manero, Hagop Kantarjian, Amin Alousi, Chitra Hosing, Paolo Anderlini, Issa F. Khouri, Partow Kebriaei, Borje S. Andersson, Betul Oran, Katayoun Rezvani, David Marin, Elizabeth J. Shpall, Richard E. Champlin & Stefan O. Ciurea. (2016) Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation 22:1, pages 47-53.
Crossref
Crossref
Kristen B. McCullough & Mrinal M. Patnaik. (2015) Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update. Current Hematologic Malignancy Reports 10:3, pages 292-302.
Crossref
Crossref
Qi Shen, Juan Ouyang, Guilin Tang, Elias J. Jabbour, Guillermo Garcia-Manero, Mark Routbort, Sergej Konoplev, Carlos Bueso-Ramos, L. Jeffrey Medeiros, Jeffrey L. Jorgensen & Sa A. Wang. (2015) Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. European Journal of Haematology 95:2, pages 168-176.
Crossref
Crossref
Mrinal M. Patnaik, Sameer A. Parikh, Curtis A. Hanson & Ayalew Tefferi. (2014) Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. British Journal of Haematology 165:3, pages 273-286.
Crossref
Crossref
Lisa Pleyer, Ulrich Germing, Wolfgang R. Sperr, Werner Linkesch, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Martin Schreder, Michael Pfeilstocker, Alois Lang, Thamer Sliwa, Dietmar Geissler, Konstantin Schlick, Gudrun Placher-Sorko, Georg Theiler, Josef Thaler, Martina Mitrovic, Daniel Neureiter, Peter Valent & Richard Greil. (2014) Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia Research 38:4, pages 475-483.
Crossref
Crossref
Sameer A. Parikh & Ayalew Tefferi. (2013) Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. American Journal of Hematology 88:11, pages 967-974.
Crossref
Crossref
Massimo Breccia, Maria Teresa Voso & Giuliana Alimena. (2013) Chronic myelomonocytic leukemia treatment with azacitidine: What have we learned so far?. Leukemia Research 37:2, pages 204-205.
Crossref
Crossref
Sonja Burgstaller. (2013) Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications. memo - Magazine of European Medical Oncology 6:1, pages 32-36.
Crossref
Crossref